EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gensight Biologics's enterprise value is €56.30 Mil.
Gensight Biologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-20.89 Mil. Therefore, Gensight Biologics's EV-to-EBITDA for today is -2.69.
The historical rank and industry rank for Gensight Biologics's EV-to-EBITDA or its related term are showing as below:
XPAR:SIGHT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.33 Med: -3.64 Max: -0.88
Current: -2.69
During the past 12 years, the highest EV-to-EBITDA of Gensight Biologics was -0.88. The lowest was -9.33. And the median was -3.64.
XPAR:SIGHT's EV-to-EBITDA is ranked worse than 100% of 458
companies
in the Biotechnology industry
Industry Median: 10.31
vs XPAR:SIGHT: -2.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Gensight Biologics EV-to-EBITDA Historical Data
The historical data trend for Gensight Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gensight Biologics's EV-to-EBITDA
For the Biotechnology subindustry, Gensight Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's EV-to-EBITDA falls into.
Gensight Biologics's current Enterprise Value is €56.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-20.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Gensight Biologics's PE Ratio for today is calculated as:
Gensight Biologics's share price for today is €0.394.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.540.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Gensight Biologics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Gensight Biologics (XPAR:SIGHT) Business Description
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XPAR:SIGHT has been successfully added to your 